Meili Sun

机构：Shandong University, Jinan Central Hospital, Shandong First Medical University · ORCID：0000-0002-4914-6508

发表论文 210 篇 · 总被引 4170 次 · h-index 31

代表论文

• CLDN18.2–targeting antibody–drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial (2025 · Nature Medicine · 被引 40)
• A bispecific antibody–drug conjugate targeting EGFR and HER3 in metastatic esophageal squamous cell carcinoma: a phase 1b trial (2025 · Nature Medicine · 被引 19)
• Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial (2025 · The Lancet Oncology · 被引 16)
• Efficacy and safety of IBI351 (fulzerasib) monotherapy in KRASG12C inhibitor-naïve Chinese patients with KRASG12C-mutated metastatic colorectal cancer: a pooled analysis from phase I part of two studies (2025 · Signal Transduction and Targeted Therapy · 被引 14)
• Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial (2025 · The Lancet Respiratory Medicine · 被引 13)
• Tecotabart vedotin in Claudin 18.2-positive advanced gastric/gastroesophageal junction cancer: A Bayesian phase 1/2 clinical trial (2025 · European Journal of Cancer · 被引 11)